Treace Medical Concepts (TMCI) Projected to Post Quarterly Earnings on Friday

Treace Medical Concepts (NASDAQ:TMCI) will likely be announcing its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $45.96 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 8, 2026 at 8:00 AM ET.

Treace Medical Concepts (NASDAQ:TMCI) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The business had revenue of $62.52 million during the quarter, compared to analysts’ expectations of $61.76 million. Treace Medical Concepts had a negative return on equity of 59.91% and a negative net margin of 27.74%. On average, analysts expect Treace Medical Concepts to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Treace Medical Concepts Price Performance

TMCI stock traded up $0.02 during midday trading on Wednesday, hitting $1.90. 13,599 shares of the stock were exchanged, compared to its average volume of 782,859. The stock’s 50-day moving average price is $1.62 and its 200-day moving average price is $2.71. The stock has a market cap of $122.77 million, a price-to-earnings ratio of -1.99 and a beta of 1.10. Treace Medical Concepts has a fifty-two week low of $1.17 and a fifty-two week high of $7.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.13 and a current ratio of 4.31.

Hedge Funds Weigh In On Treace Medical Concepts

A number of institutional investors have recently made changes to their positions in the stock. Invesco Ltd. raised its holdings in shares of Treace Medical Concepts by 18.6% in the second quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock worth $88,000 after acquiring an additional 2,362 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Treace Medical Concepts by 328.3% in the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after acquiring an additional 3,674 shares during the last quarter. Parkman Healthcare Partners LLC raised its holdings in shares of Treace Medical Concepts by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 847,675 shares of the company’s stock worth $5,688,000 after acquiring an additional 3,677 shares during the last quarter. Barclays PLC raised its holdings in shares of Treace Medical Concepts by 7.4% in the fourth quarter. Barclays PLC now owns 87,664 shares of the company’s stock worth $215,000 after acquiring an additional 6,077 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Treace Medical Concepts by 5.1% in the second quarter. BNP Paribas Financial Markets now owns 162,976 shares of the company’s stock worth $958,000 after acquiring an additional 7,898 shares during the last quarter. 84.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TMCI shares. Stifel Nicolaus reduced their price objective on Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating for the company in a report on Wednesday, January 7th. Lake Street Capital reduced their price objective on Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Monday, April 20th. Finally, Wall Street Zen raised Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $4.77.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.